Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AMINOSYN II 10% is an injectable amino acid formulation used for parenteral nutrition in hospitalized patients requiring intravenous nutritional support. It provides essential and non-essential amino acids to maintain protein synthesis and metabolic function in patients unable to tolerate oral or enteral feeding. The product works by delivering a balanced mixture of amino acids directly into the bloodstream for systemic utilization.
Product is in late-stage lifecycle with moderate competitive pressure (30% intensity), indicating potential team consolidation and transition planning underway.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Bioavailability of Plant Protein Amino Acids
Worked on AMINOSYN II 10% at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on AMINOSYN II offers stability in a mature, established product with established hospital relationships, but limited growth potential given LOE approach. Career progression would emphasize operational excellence, cost management, and transition planning rather than market expansion or innovation.